Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer

By sjmartinez • February 27, 2025

Podany EL, Foffano L, Gerratana L, Medford AJ, Clifton K, Tapiavala S, Velimirovic M, Lipsyc-Sharf M, Reduzzi C, Bubie A, Putur A, Ademuyiwa FO, Puglisi F, Gradishar WJ, Ma CX, Bardia A, Cristofanilli M, Davis AA. Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer. JAMA Netw Open. 2025 Feb 3;8(2):e2461899. doi: 10.1001/jamanetworkopen.2024.61899. PMID: 40009379.

Tags: Hematology/Oncology, Publications

Related Posts

Correction: Hao et al. Enhanced Chemoprevention of Prostate Cancer by Combining Arctigenin with Green Tea and Quercetin in Prostate-Specific Phosphatase and Tensin Homolog Knockout Mice. Biomolecules 2024, 14, 105

Hao Q, Henning SM, Magyar CE, Said J, Zhong J, Rettig MB, Vadgama JV, Wang P. Correction: Hao et al. Enhanced Chemoprevention of Prostate Cancer[...]

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo[...]

Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen[...]